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Abstract
To estimate the incidence, prevalence, and survival of systemic sclerosis in the United Kingdom. We conducted a historical
cohort study using data from the Clinical Practice Research Datalink (CPRD). We calculated the incidence and survival of
systemic sclerosis between 1994 and 2013 and examined its association with age, sex, and socioeconomic status. We calculated
point prevalence on 1 July 2013 and examined its association with the same exposures. We identified 1327 cases with incident
systemic sclerosis. Annual incidence was 19.4 per million person-years between 1994 and 2013. The incidence was 4.7 times
higher in women than inmen, was not influenced by socioeconomic status, and has remained stable over the 20 year study period.
The peak age of onset was 55–69 years. Survival at 1, 5, and 10 years was 94.2, 80.0, and 65.7%, respectively. The prevalence
was 307 (290–323) per million with the highest prevalence in the 70–84 years age group. We estimate there are currently 1180
new cases of systemic sclerosis each year in the UK, and 19,390 people living with systemic sclerosis. Due to the predicted
growth and aging of the population, we predict a 24% increase in incident cases and 26% increase in prevalent cases in 20 years’
time. Our estimates of incidence and prevalence are higher than previously reported in the UK, but similar to recent USA and
Swedish studies, and do not support a north-south gradient of the occurrence of systemic sclerosis in Europe.
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Introduction
Systemic sclerosis is a rare autoimmune disease of unknown
etiology characterized by skin fibrosis and internal organ in-
volvement. The incidence and prevalence of systemic sclero-
sis have been reported to varywidely with incidence estimated
between 4 and 43/million person years [1–3], and prevalence
between 88 and 443/million [4, 5]. It seems the incidence and
prevalence may be influenced by race [6, 7], but whether there
are true geographical differences in occurrence in Caucasian
populations is less clear.
The literature before 2006 is summarized in a systematic
review [8], which proposed a North-South gradient in
Europe with lower rates in Northern European countries
(UK, Finland, and Iceland [1, 2, 5, 9]) compared to
Southern European ones (France and Greece [7, 10]).
Studies published since this have continued to report high
incidences in Southern Europe (Spain, Croatia and Italy)
[3, 11, 12] but contradictory rates in Northern Europe with
low annual incidence of 6–11 per million in Norway [13]
and a higher rate 19/million person-years in Southern
Sweden [14]. Incidence and prevalence in the USA,
Canada, and Australia are reported at the higher end of this
range [4, 15, 16].
Previous studies of the epidemiology of systemic scle-
rosis in the UK were small [1, 5, 17], and the epidemiol-
ogy of systemic sclerosis has never been examined in a
nationwide population-based study, which reduces the
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biases that are inherent in smaller hospital-based studies.
The availability of Clinical Practice Research Datalink
(CPRD) (a longitudinal database of consultation based pa-
tient records from UK general practice) gives us an oppor-
tunity to examine the epidemiology of systemic sclerosis
in a large population that is representative of the UK pop-
ulation [18].
Understanding the incidence and prevalence of systemic
sclerosis will help to address the healthcare needs and aid
service planning for this rare disease, both now and in the
future. Such service planning may include the setting up,
staffing, and resourcing of specialist treatment centers. It
may also add to the debate about whether occurrence of sys-
temic sclerosis is lower in Northern Europe.
The aim of this study was to estimate the incidence, prev-
alence, and mortality rates of systemic sclerosis in the UK and
to explore temporal trends in its incidence. We also investigat-
ed the effects of age, sex, and socioeconomic status on inci-
dence, prevalence, and mortality.
Patients and methods
Study design and population
The UK healthcare system is well-suited to capturing diseases
which are managed both in hospitals and in the community. In
the UK, everybody is registered with a general practitioner
(GP) who co-ordinates their healthcare including referrals to
secondary care. For example, when a patient is discharged
from hospital, or attends a hospital clinic, a letter is written
to inform the GP of any new diagnoses, and these are added to
the GP record. By using GP data, we would expect to capture
people with the full spectrum of scleroderma, from the mildest
to the most severe, and would not expect to need to interrogate
hospital databases or discharge letters from hospital to identify
additional cases.
This is a historical cohort study containing all 684 gen-
eral practices contributing data to the CPRD in 2015. The
CPRD is a longitudinal general practice database of ap-
proximately 13 million people who have contributed data
since 1987, and approximately 6% of the UK population
are currently contributing data [19]. The database contains
general practices from all four countries in the UK and
includes information on demographics, diagnoses, refer-
rals, medications, and tests. It is deemed to be representa-
tive of the UK population [18, 20]. We followed the
CPRD’s recommendations for selecting research quality
patient records and periods of quality data recording by
including people contributing Bacceptable^ quality data in
Bup to standard^ practices. Our study was conducted be-
tween 1 January 1994 and 31 December 2013.
Case definition
We compiled lists of Read codes for a diagnosis of systemic
sclerosis by searching the description fields of the Read code
dictionary and excluding irrelevant codes, using a method
described by Dave and Petersen [21]. Synonyms searched
for were systemic sclerosis, scleroderma, and CREST. Only
Read codes that were specific for a diagnosis of systemic
sclerosis were used, and codes for localized scleroderma were
excluded. Read codes are available as an online supplement
and at clinicalcodes.org [22]. We did not validate the
diagnosis of systemic sclerosis externally, because (1) valida-
tion of other chronic autoimmune diseases in the CPRD has
shown positive predictive values of > 90% [23, 24], and (2)
GPs would be unlikely to give a patient a Read code for
systemic sclerosis unless it had been confirmed by a hospital
specialist [25]. Incident cases were defined as people with a
first record of a Read code during the study period, and prev-
alent cases were people who had ever had a code for systemic
sclerosis. We only included incident cases with a least 1 year
of disease-free follow up in the CPRD prior to their diagnosis
in order to reduce the chance of prevalent cases being
misclassified as incident cases [26].
Data sources
All data were extracted from the CPRD files except for the
2010 English Index of Multiple Deprivation (IMD10) which
was used as a proxy for socioeconomic status. IMD10 was
supplied, via a linkage agreement, by the Office for National
Statistics (ONS) and was available for patients in English
practices that had consented to participate in the linkage
scheme (~ 60%) [27].
Statistical analysis
We categorized age into groups (0–15, 16–39, 40–54, 55–69,
70–84, and 85+ years) and used IMD-10 quintiles, where
quintile 1 is the most deprived, and quintile 5 the least de-
prived. A further Bmissing^ IMD category was created to
maintain all participants in the analyses.
We calculated crude incidence rates, and stratified these by
age group, sex, year of diagnosis, and IMD-10 quintile. The
denominator was all people contributing acceptable quality
data in up to standard practices to the CPRD during the study
period. Unadjusted incidence rate ratios were obtained by
fitting variables individually in separate Poisson regression
models. Mutually adjusted incidence rate ratios were obtained
by fitting age group, sex, and IMD-10 quintiles as a priori
confounders in a single Poisson regression model.
We calculated point prevalence per million people on 1
July 2013 and stratified this in the same way as for incidence.
To calculate this, we divided the number of people with a
2104 Clin Rheumatol (2018) 37:2103–2111
Read code for systemic sclerosis who were alive and contrib-
uting data on this date by the total number of people alive and
contributing data on this date. We used logistic regression
models to calculate odds ratios (ORs) and 95% confidence
intervals (CIs), which provides a good estimation of the rela-
tive risk for rare outcomes such as this. Unadjusted ORs were
obtained by fitting variables individually in separate logistic
regression models. Mutually adjusted ORs were obtained by
fitting age group, sex, and IMD-10 quintiles as a priori con-
founders in a single logistic regression model.
Kaplan-Meier methods were used to estimate survival at 1,
5, and 10 years after diagnosis. We used Cox regression to
estimate hazard ratios (HRs) for the effect of sex, age group,
and IMD-10 quintile on mortality. Unadjusted HRs were ob-
tained by fitting variables individually in separate Cox regres-
sion models. Mutually adjusted HRs were obtained by fitting
age group, sex, and IMD-10 quintiles as a priori confounders
in a single Cox regression model.
We used direct standardization of the age-specific inci-
dence rates to the ONS age-stratified UK population now
and projected UK population in 20 years, to estimate the num-
ber of expected incident and prevalent cases in the UK now
and in 2037, assuming that incidence will not change over the
next 20 years.
All analyses were performed using Stata 14 statistical soft-
ware (Statacorp, Texas, USA).
Ethics
Independent Scientific Advisory Committee (ISAC) for
MHRA Database Research approval was obtained for this
study on October 26, 2016 (protocol 16_190R).
Reporting guidelines
This study has been reported following the RECORD guide-
lines for reporting of studies conducted using observational
routine-collected health data [28].
Results
Overall, we identified 1327 cases of systemic sclerosis in
the CPRD during the study period (Fig. 1). Of these, 83.2%
were female and the mean age at diagnosis was 58.0 years
(SD 16.4).
Incidence
The estimated overall incidence of systemic sclerosis in the
entire CPRD population was 19.4 per million person-years
(95% confidence interval (CI) 18.3–20.4) (Table 1). The inci-
dence in adults aged ≥ 16 was 22.8 (95% CI 21.6–24.1) per
million person-years and in children aged < 16 years was 2.9
(95% CI 2.1–4.1) per million person-years (Table 2).
Temporal trend
The incidence of systemic sclerosis did not change significant-
ly between 1994 and 2013 (Table 1), adjusted rate ratio 0.6%
increase per year (P = 0.24).
Age, sex, socioeconomic status
The crude and adjusted incidence rate ratios are listed in Table
2. Incidence was higher among women than in men with an
adjusted incidence rate ratio of 4.7 (95% CI 4.1–5.4), P <
0.0001. People aged 55–69 years had the highest incidence
of systemic sclerosis. Socioeconomic status was not associat-
ed with incidence of systemic sclerosis, Ptrend 0.63.
Prevalence
Overall point prevalence in 2013 was 307 (95% CI 290–323)
per million (Table 3). Prevalence was higher in women (ad-
justed OR 4.6, 95% CI 3.9–5.2, P < 0.0001) and highest in the
70–84 years category (835 per million, 95% CI 751–925),
followed by the 55–69 years category (669 per million, 95%
CI 612–730). There was no association between socioeco-
nomic status and prevalence of systemic sclerosis, Ptrend 0.68.
Survival
Over the study period, there were 302 deaths during
6929 years at risk contributed by people with incident system-
ic sclerosis generating a mortality rate of 43.6 (95% CI 38.9–
48.8) per thousand person-years (Table 4). Risk factors for
increased mortality were male sex and increasing age.
However, there was no association between socioeconomic
deprivation and mortality. The 1-, 5-, and 10-year survival
was 94.2, 80.0, and 65.7% respectively.
Estimated UK incidence and prevalence
We estimate that at present, there are 1180 new cases of
systemic sclerosis each year in the UK and 19,390 people
living with systemic sclerosis. Population projections show
a large expected increase in the proportion of the UK pop-
ulation in the 55+ age group [29] in 20 years’ time, mean-
ing that we estimate in 2037, there will be 1460 new cases
(24% increase) and 24,430 people living with systemic
sclerosis (26% increase).
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Discussion
Main findings
Using the CPRD, we estimate that the annual incidence of
systemic sclerosis in the UK population is 19.4 per million
person-years. The incidence is nearly five times higher in
women than in men, is not influenced by socioeconomic sta-
tus, and has remained stable over the 20-year study period.
The peak age of onset is 55–69 years. We estimate the UK
prevalence of systemic sclerosis in the UK population is 307
(290–323) per million with the highest prevalence in the 70–
84 years age group.
How our study fits in with other literature
Our study estimated incidence and prevalence in the UK to be
higher than previously reported in Norway, Croatia, Greece,
France, Taiwan, and Australia [6, 7, 10, 12, 13, 16], similar to
the USA, Sweden, and Spain [11, 14, 15], and lower than in
Italy and Canada [3, 4]. Our findings were consistent with
other large population-based studies in Caucasians. A large
study in the Detroit tri-county area of the USA between
1989 and 1991 estimated the incidence of systemic sclerosis
to be 19.3 per million but with a lower prevalence of 242 per
million, using 5 data sources including hospital records and a
capture-recapture analysis [15]. A more recent study conduct-
ed in southern Sweden used a health register of 1.2 million
pooled public and private health care records between 2006
and 2010 and estimated an incidence of 19 per million and a
prevalence of 305 per million [14]. This study had approval to
retrospectively review the medical records and validate the
diagnosis of systemic sclerosis with reference to the 1980
ARA criteria [30], and the similarity between our findings
support the reliability of our case ascertainment. Taken togeth-
er [14], our studies challenge the idea that the prevalence of
systemic sclerosis is lower in Europe than in the USA and
Australia [8], or that it is lower in Northern Europe compared
to Southern Europe [8].
Our estimates of incidence and prevalence are much higher
than previous UK estimates. Our study is the first nationwide
UK study of incidence and prevalence of systemic sclerosis,
and the first of a prospectively collected healthcare database.
Our estimate of incidence among adults is more than 4 times
higher than the previous estimates of 4 per million from the
west Midlands in the 1980s [1], and our estimate of incidence
Fig. 1 Flow diagram of
ascertainment of incident cases of
systemic sclerosis. Cases of
systemic sclerosis ascertained
from the Clinical Practice
Research Datalink 1994–2013
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among children was 10 times higher than the previous esti-
mate of 0.27/million across the whole UK in 2010 [31]. Our
estimate of prevalence is 3.5 times higher than the most recent
estimate of 8.4 per million from North East England in 2004
[5]. The lower incidence and prevalence reported previously
are likely to be methodological, caused by under-estimation of
cases in these studies due to their reliance on physicians (na-
tionally or in a limited geographical area) being asked to re-
cord cases of systemic sclerosis attending their clinics and
reporting this to the authors [1, 31], or on physician recall
[5] which are not as reliable as prospectively recorded diag-
noses in the patient’s general practice record.
The higher incidence and prevalence among women than
men is well-recognized. Ours is the first study to report the
effect of socioeconomic status on the incidence of systemic
sclerosis; we observed no effect of socioeconomic status, as
estimated by area-based deprivation data which is used as a
proxy for socioeconomic status and social class. This lack of
effect is in contrast to other autoimmune diseases such as
rheumatoid arthritis and systemic lupus erythematosus where
increasing deprivation is associated with increased incidence
and disease severity [32–34]. Survival at 1, 5, and 10 years of
94.2, 80.0, and 65.7% respectively is very similar to the
pooled estimates from an international meta-analysis of
mortality in systemic sclerosis using individual patient data
[35]. Mortality was increased in older people, and possibly
men compared to women, but unaffected by socioeconomic
status.
The mean age of diagnosis in our study was 58 years (SD
16.4 years). While this is consistent with a previous UK study
[5] and a study using inpatient and outpatient healthcare data-
bases in Northern Italy [3], it is higher than the established
teaching that onset is greatest from early adulthood to the 4th
decade [36] and higher than most recent studies which report
the mean age of onset as 45–48 years [1, 6, 7]. It is unclear
why this is. It could be that there are longer delays between
symptoms onset and diagnosis in our healthcare system than
in others. There is also a possible delay after the diagnosis and
before it is recorded in the CPRD. Such delay has recently
been quantified in rheumatoid arthritis in the CPRD and was
found to be < 2 years [37].
Systemic sclerosis is an important condition for rheu-
matologists, because although rare, it has a very high
mortality compared to other musculoskeletal diseases
[38], and optimal patient care is challenging and in-
volves multidisciplinary effort. We have found a much
higher incidence and prevalence of systemic sclerosis in
the UK than previously reported [38] and in addition
have estimated that the burden on our healthcare ser-
vices will increase by 25% over the next 20 years as
a result of changes in population demographics.
Strengths
This study is the first nationwide European study and
largest of its kind in Europe. The main strength of our
study is the use of the CPRD dataset. It is the largest
primary care database, containing more than 13 million
patient records and covering approximately 6% of the
UK population. It has been validated as a representative
dataset so results can be applied to the UK population
as a whole [20]. It has good quality demographic data,
allowing us to study the influence of age, sex, and
socioeconomic status on incidence, prevalence, and sur-
vival of systemic sclerosis. It has allowed us to conduct
a population-based study in a prospectively collected
dataset, which avoids the selection bias of cohort stud-
ies from tertiary referral centers and recall bias of stud-
ies relying on physician memory.
Limitations
Systemic sclerosis is a rare disease, and the number of cases
identified is small in comparison with some other conditions.
Despite this, we have identified a cohort of more than 1300
people with systemic sclerosis which allows us to make the
most precise estimates of incidence, prevalence, and survival
Table 1 Annual incidence of systemic sclerosis 1994–2013 per million
person-years in the Clinical Datalink
Year Incident cases Person- years Incidence rate (95% CI)
1994 32 1,304,220 24.5 (17.4–34.7)
1995 36 1,406,927 25.6 (18.5–35.5)
1996 31 1,596,103 19.4 (13.7–27.6)
1997 30 1,884,001 15.9 (11.1–22.8)
1998 24 2,123,764 11.3 (7.6–16.9)
1999 47 2,576,123 18.2 (13.7–24.3)
2000 47 3,150,278 14.9 (11.2–19.9)
2001 58 3,459,183 16.8 (13.0–21.7)
2002 81 3,815,730 21.2 (17.1–26.4)
2003 79 4,039,225 19.6 (15.7–24.4)
2004 76 4,236,700 17.9 (14.3–22.5)
2005 92 4,352,147 21.1 (17.2–25.9)
2006 86 4,396,878 19.6 (15.8–24.2)
2007 94 4,434,807 21.2 (17.3–25.9)
2008 77 4,441,042 17.3 (13.9–21.7)
2009 82 4,451,968 18.4 (14.8–22.9)
2010 82 4,386,173 18.7 (15.1–23.2)
2011 103 4,285,455 24.0 (19.8–29.2)
2012 96 4,210,630 22.8 (18.7–27.8)
2013 74 3,978,397 18.6 (14.8–23.4)
Overall incidence = 19.4 (95% CI 18.3–20.4) per million person-years
(1327 cases in 68,529,750 person-years)
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Table 3 Point prevalence of systemic sclerosis in 2013 (per million people)





Overall 1337 4,362,809 307 (290–323)
Sex
Male 227 2,155,960 105 (92–120) 1 1 P < 0.0001
Female 1110 2,206,814 503 (474–533) 4.8 (4.1–5.5) 4.6 (3.9–5.2)
Age group (years)
Age 0–15 13 781,568 17 (9–28) 0.2 (0.1–0.4) 0.2 (0.1–0.4) Ptrend < 0.0001
Age 16–39 111 1,322,291 84 (69–101) 1 1
Age 40–54 283 959,587 295 (262–331) 3.5 (2.8–4.4) 3.5 (2.8–4.4)
Age 55–69 505 754,643 669 (612–730) 8.0 (6.5–9.8) 7.9 (6.5–9.8)
Age 70–84 362 433,661 835 (751–925) 10.0 (8.0–12.3) 9.4 (7.6–11.7)
Age 85+ 63 111,059 567 (436–726) 6.8 (5.0–9.2) 5.6 (4.1–7.7)
IMD 2010
Quintile 1 188 600,110 313 (270–361) 1 1 Ptrend = 0.68
Quintile 2 188 598,616 314 (271–362) 1.0 (0.8–1.2) 1.0 (0.8–1.2)
Quintile 3 147 519,240 283 (239–333) 0.9 (0.7–1.1) 0.9 (0.8–1.2)
Quintile 4 145 520,410 279 (235–328) 0.9 (0.7–1.1) 1.0 (0.8–1.3)
Quintile 5 110 424,476 259 (213–312) 0.8 (0.7–1.0) 1.1 (0.8–1.3)
IMD not known 559 1,699,957 329 (302–357) 1.0 (0.9–1.2) 1.1 (0.9–1.3)
Crude odds ratio is calculated using univariable logistic regression, and adjusted odds ratio is calculated usingmulti-variable logistic regression including
sex, age group, and IMD-quintile as a priori confounders
a From multi-variable (adjusted) analysis using the likelihood ratio test










Overall 1327 68,529,194 19.4 (18.3–20.4)
Sex
Male 223 34,069,626 6.5 (5.7–7.5) 1 1 < 0.0001
Female 1104 34,459,569 32.0 (30.2–34.0) 4.9 (4.2–5.7) 4.7 (4.1–5.4)
Age group (years)
Age 0–15 35 11,955,198 2.9 (2.1–4.1) 0.5 (0.3–0.7) 0.5 (0.3–0.7) Ptrend < 0.0001
Age 16–39 132 20,729,227 6.4 (5.4–7.6) 1 1
Age 40–54 338 15,329,346 22.0 (19.8–24.5) 3.5 (2.8–4.2) 3.4 (2.8–4.2)
Age 55–69 513 11,887,368 43.2 (39.6–47.1) 6.7 (5.6–8.2) 6.7 (5.5–8.1)
Age 70–84 283 7,100,416 39.9 (35.3–44.8) 6.3 (5.1–7.7) 5.7 (4.6–7.0)
Age 85+ 26 1,528,196 17.0 (11.6–25.0) 2.7 (1.8–4.1) 2.1 (1.4–3.1)
Each additional calendar year 1.0 (1.0–1.0) Ptrend 0.24
IMD 2010
Quintile 1—most deprived 196 9,911,807 19.8 (17.2–22.7) 1 1 Ptrend = 0.63
Quintile 2 187 9,728,120 19.2 (16.7–22.2) 1.0 (0.8–1.2) 0.9 (0.8–1.2)
Quintile 3 157 8,356,976 18.8 (16.1–22.0) 1.0 (0.8–1.2) 1.0 (0.8–1.2)
Quintile 4 152 7,802,398 19.5 (16.6–22.8) 1.0 (0.8–1.2) 1.1 (0.9–1.3)
Quintile 5—least deprived 120 6,304,656 19.0 (15.9–22.7) 1.0 (0.8–1.2) 1.1 (0.9–1.4)
IMD not known 515 26,425,793 19.5 (17.9–21.2) 1.0 (0.8–1.2) 1.0 (0.9–1.2)
Crude incidence rate is calculated using univariable Poisson regression, and the adjusted rate ratio is calculated using multi-variable Poisson regression
including sex, age-group, year of diagnosis and IMD-quintile as a priori confounders
a From multi-variable (adjusted) analysis using the likelihood ratio test
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published in a European population, which are essential for
health service planning.
Within the CPRD, it is not possible to externally validate
the date of diagnosis and accuracy of diagnosis of systemic
sclerosis. In the past, it was possible to request anonymized
sets of hospital correspondence, but this service has beenwith-
drawn by the CPRD to increase the confidentiality of the
database. Previous studies of the accuracy of the recording
of diagnosis of similar chronic diseases in the CPRD have
shown positive predictive values (PPVs) > 90% [39]. For ex-
ample, the PPVof codes for granulomatosis with polyangiitis
(formerly known as Wegener’s granulomatosis) and idiopath-
ic thrombocytopenic purpura were both found to be 91% [23,
24]. There is no reason to believe it should be dissimilar in
systemic sclerosis because a diagnosis of all of these serious
autoimmune diseases are very unlikely to be recorded by a GP
without confirmation from secondary care, where the diagno-
sis would have been made [25, 40]. It is therefore also not
possible to apply classification criteria, but our study repre-
sents people considered to have systemic sclerosis by their
physicians. It is also unknown how many people may be un-
diagnosed, which means that our estimates, like all others, are
likely to be underestimates of incidence and prevalence.
The Read codes do not allow cases to be differentiated into
diffuse cutaneous and limited cutaneous phenotypes of
systemic disease; however, we have excluded morphoea and
other localized forms of cutaneous only disease. Our study
therefore contains people with systemic sclerosis but cannot
comment on differences between diffuse and limited cutane-
ous phenotypes.
Conclusion
We found the UK incidence and prevalence of systemic scle-
rosis to be higher than previously reported in the UK but
similar to other recent USA and European estimates [14,
15]. Our findings suggest that systemic sclerosis is not less
common in Europe than in the USA and Australia and not less
common in northern Europe compared to southern Europe.
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Table 4 Mortality of systemic sclerosis 1994–2013 (per thousand person-years)





Overall 1327 302 6929 43.6 (38.9–48.8)
Sex
Male 223 53 1119 47.4 (36.2–62.0) 1 1 P = 0.06
Female 1104 249 5810 42.9 (37.9–48.5) 0.9 (0.7–1.2) 0.7 (0.5–1.0)
Age group (years)
Age 0–15 35 1 136 7.4 (1.0–52.2) 1.2 (0.1–11.9) 1.2 (0.1–11.4) Ptrend < 0.0001
Age 16–39 146 3 501 6.0 (1.9–18.6) 1 1
Age 40–54 390 20 1572 12.7 (8.2–19.7) 2.2 (0.6–7.3) 1.2 (0.7–7.6)
Age 55–69 668 89 2923 30.4 (24.7–37.5) 5.4 (1.7–17.0) 5.7 (1.8–17.9)
Age 70–84 473 152 1616 94.1 (80.3–110.3) 16.7 (5.3–52.3) 17.7 (5.6–55.7)
Age 85+ 75 37 182 203.7 (147.6–281.2) 36.2 (11.1–117.8) 37.8 (11.6–123.2)
IMD 2010b
Quintile 1 196 45 1048 42.9 (32.1–57.5) 1 1 Ptrend = 0.49
Quintile 2 187 42 999 42.1 (31.1–56.9) 1.0 (0.6–1.5) 1.0 (0.7–1.6)
Quintile 3 157 36 702 51.3 (37.0–71.1) 1.2 (0.8–1.8) 1.0 (0.6–1.5)
Quintile 4 152 37 795 46.6 (33.7–64.3) 1.1 (0.7–1.7) 1.0 (0.7–1.6)
Quintile 5 120 37 628 58.9 (42.7–81.3) 1.3 (0.9–2.1) 1.2 (0.8–1.9)
IMD not known 515 105 2758 38.1 (31.4–46.1) 0.9 (0.6–1.3) 0.9 (0.6–1.2)
Crude hazard ratio is calculated using univariable Cox regression, and adjusted hazard ratio is calculated using multi-variable Cox regression including
sex, age group, and IMD-quintile as a priori confounders
a From multi-variable (adjusted) analysis, using the likelihood ratio test
b Quintile 1 is the most deprived, Quintile 5 is the least deprived
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distribution, and reproduction in any medium, provided you give appro-
priate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
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